RXST Share Price Performance
US$6.26
-18.44 (-74.66%)
87.5% undervalued intrinsic discount
US$50.00
Fair Value
Price US$6.26
HighMarginJoey US$50.00
AnalystConsensusTarget US$10.06
AnalystLowTarget US$8.00
Fair ValueUS$50.00
Share Pricen/a
RxSight, Inc. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 16 Fair Values set on narratives written by author
RXST Community Narratives
HI
Fair Value US$50 87.5% undervalued intrinsic discount
Is This Lens Maker Mispriced? A Blind Spot in Plain Sight
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$10.06 37.7% undervalued intrinsic discount
Entry Into European And Asian Markets Will Unlock New Opportunities
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
Fair Value US$8 21.8% undervalued intrinsic discount
Premium Cataract Focus And Rising Costs Will Limit Long Term Earnings Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Is This Lens Maker Mispriced? A Blind Spot in Plain Sight
RxSight (NASDAQ: RXST), maker of the only cataract lens that can be adjusted post-surgery, could be undervalued by an eye-popping margin More than 70% of RxSight Light Adjustable Lens (LAL) patients reported 20/20 or better vision after receiving the lens. Only 36.3% of non-adjustable lens patients reported the same.Read more
117
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
HI
US$50
87.5% undervalued intrinsic discount
Fair Value
Profit Margin
30%
Future PE
20x
Price in 2036
US$105.18
Entry Into European And Asian Markets Will Unlock New Opportunities
Key Takeaways Strategic realignment and international expansion target higher adoption, utilization, and new revenue streams, leveraging demographic trends and a growing emphasis on vision correction. Investments in innovation, education, and clinical support aim to broaden market share, enhance margins, and build long-term pricing power within the premium IOL segment.Read more
101
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
US$10.06
37.7% undervalued intrinsic discount
Fair Value
Profit Margin
12.86%
Future PE
28.36x
Price in 2029
US$12.52
Premium Cataract Focus And Rising Costs Will Limit Long Term Earnings Potential
Catalysts About RxSight RxSight develops and sells the Light Adjustable Lens and Light Delivery Device system for cataract patients seeking customized visual outcomes. What are the underlying business or industry changes driving this perspective?Read more
1
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$8
21.8% undervalued intrinsic discount
Fair Value
Profit Margin
12.9%
Future PE
21.36x
Price in 2029
US$10
Premium Cataract Adoption And International Expansion Will Drive Strong Long Term Potential
Catalysts About RxSight RxSight develops and commercializes the Light Adjustable Lens system to deliver personalized cataract surgery outcomes through postoperative adjustability. What are the underlying business or industry changes driving this perspective?Read more
8
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$13.35
53.1% undervalued intrinsic discount
Fair Value
Profit Margin
12.91%
Future PE
34.53x
Price in 2028
US$16.68
Trending Discussion
Recently Updated Narratives
HI
Is This Lens Maker Mispriced? A Blind Spot in Plain Sight
Fair Value: US$50 87.5% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
RXST: Future Returns Will Hinge On New CFO And 2026 Guidance
Fair Value: US$10.06 37.7% undervalued intrinsic discount
11 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Premium Cataract Focus And Rising Costs Will Limit Long Term Earnings Potential
Fair Value: US$8 21.8% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
RxSight, Inc. Key Details
About RXST
- Founded
- 1997
- Employees
- 461
- CEO
- WebsiteView website
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.
